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Abstract
Background: The foamy virus Pol protein is translated independently from Gag using a separate mRNA. Thus, in
contrast to orthoretroviruses no Gag-Pol precursor protein is synthesized. Only the integrase domain is cleaved off
from Pol resulting in a mature reverse transcriptase harboring the protease domain at the N-terminus (PR-RT).
Although the homology between the PR-RTs from simian foamy virus from macaques (SFVmac) and the prototype
foamy virus (PFV), probably originating from chimpanzee, exceeds 90%, several differences in the biophysical and
biochemical properties of the two enzymes have been reported (i.e. SFVmac develops resistance to the nucleoside
inhibitor azidothymidine (AZT) whereas PFV remains AZT sensitive even if the resistance mutations from SFVmac
PR-RT are introduced into the PFV PR-RT gene). Moreover, contradictory data on the monomer/dimer status of the
foamy virus protease have been published.
Results: We set out to purify and directly compare the monomer/dimer status and the enzymatic behavior of the
two wild type PR-RT enzymes from SFVmac and PFV in order to get a better understanding of the protein and
enzyme functions. We determined kinetic parameters for the two enzymes, and we show that PFV PR-RT is also a
monomeric protein.
Conclusions: Our data show that the PR-RTs from SFV and PFV are monomeric proteins with similar biochemical
and biophysical properties that are in some aspects comparable with MLV RT, but differ from those of HIV-1 RT.
These differences might be due to the different conditions the viruses are confronted with in dividing and non-
dividing cells.
Background
Foamy viruses (FVs) belong to the family retroviridae,
but differ in several aspects from orthoretrovirinae:( a )
reverse transcription occurs before the virus leaves the
host cell [1,2], (b) the pol-gene is expressed from a sepa-
rate mRNA [3-5], and (c) the viral protease is not
cleaved off from the Pol polyprotein. Only the integrase
is removed from Pol [6,7]. Thus, the FV reverse tran-
scriptase harbors a protease, polymerase and RNase H
domain (PR-RT) (for review see [8,9]).
Only recently, studies have focused on the biochem-
istry of the PR-RTs of FVs. Although the PR-RTs from
simian foamy virus from macaques (SFVmac) and from
the prototype foamy virus (PFV) exhibit more than
90% sequence homology at the protein level (79.5%
identity; LALIGN, http://www.ch.embnet.org), some
differences in their behavior have been reported. Bacte-
rially expressed PFV PR-RT harbors many characteris-
tics of orthoretroviral RTs; however, FV enzymes
exhibit some peculiar features [10-16]. In comparison
to human immunodeficiency virus type 1 (HIV-1) RT,
P F VP R - R Ta p p e a r st ob eam o r ep r o c e s s i v ep o l y m e r -
ase [11]. This is probably due to differences in virus
assembly. FV Pol packaging has been reported to
require interactions of Pol with specific sequences in
the RNA genome [17], and it has been suggested that
t h e r ei sal o w e rn u m b e ro fF VP o lm o l e c u l e si nt h e
virus particle as compared to orthoretroviruses [11].
As a consequence, a highly processive polymerase is
essential to enable synthesis of the complete double
stranded genome.
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bit FV replication is azidothymidine (AZT) [1,18,19].
In in vivo experiments SFVmac acquired high resis-
tance to AZT by four mutations within the RT
sequence [14,20]. PFV, however, did not develop resis-
tance to AZT, and the introduction of the SFVmac
mutations into the PFV RT gene did not result in
viruses resistant to the nucleoside inhibitor [20].
Regarding the high amino acid homology of the two
enzymes, this result was not to be expected. In
SFVmac, the mechanism of resistance is due to the
removal of already incorporated AZT-monophosphate
(AZTMP) in the presence of ATP and thus resembles
that of HIV-1 RT [14,21,22].
It has been shown previously that retroviral PRs are
only active as homodimers. To create the active center,
each subunit of the homodimer contributes catalytic
residues located in the conserved motif DT/SG [23].
However, SFVmac PR-RT behaves as a monomer in
solution, but nevertheless exhibits PR activity. Catalytic
PR activity could only be observed at NaCl concentra-
tions of 2-3 M [15], indicating that hydrophobic inter-
actions might promote dimerization. Furthermore, by
prevalent methods the separately expressed 12.6 kDa
PR domain was also found to be monomeric but active
[15]. Only further analyses using NMR paramagnetic
relaxation enhancement proved that transient, lowly
populated dimers are being formed (Hartl MJ, Schwei-
m e rK ,R e g e rM H ,S c h w a r z i n g e rS ,B o d e mJ ,R ö s c hP ,
Wöhrl BM: Formation of transient dimers by a retro-
viral protease, submitted). Contradicting results were
obtained by gel filtration analysis with a purified C-
terminally extended 18 kDa PR domain of PFV, which
indicated that PFV PR might be dimeric [6].
To clarify these issues and to shed more light on the
properties of SFVmac and PFV PR-RT, we set out to
purify both enzymes from bacterial lysates and directly




Overexpression of PFV PR-RT in E. coli resulted in partial
degradation by cellular proteases. Thus, we could not
adopt the purification protocol established for SFVmac
PR-RT [14]. Instead, we had to set up a new purification
procedure for PFV PR-RT which includes Ni-affinity
followed by hydrophobic interaction chromatography to
remove the PR-RT degradation products. The yields were
much lower than for SFVmac PR-RT. Nevertheless, pure
soluble protein (> 95% purity, as judged from SDS-polya-
crylamide gels) could be obtained.
Biophysical properties
To exclude that the purified PR-RTs are partially or com-
pletely unfolded, we analyzed the secondary structure of
PFV and SFVmac PR-RT by circular dichroism (CD) spec-
troscopy. The shape of the CD spectra obtained for the
two enzymes was highly similar, implying comparable
ratios of a-helices and b-strands (Fig. 1A). In both cases,
the curves showed a broad minimum between 205 nm
and 222 nm, characteristic for a mixture of a-helical and
b-strand structures, and high ellipticity near 200 nm.
Thus, the spectra are indicative of predominantly folded
proteins. Although the spectrum obtained for SFVmac
PR-RT deviates slightly from that of PFV PR-RT, the cal-
culated values (Table 1) confirm the accordance in the
secondary structure contents of PFV and SFVmac PR-RT.
However, crystal structure analyses will be necessary to
obtain more information on the structural similarities and
differences of the two enzymes. The three-dimensional
structure will probably also shed more light on the differ-
ences between PFV and SFVmac PR-RT in developing
AZT-resistance.
Contradicting data have been published on the mono-
mer/dimer status of FV PRs. PFV PR expressed sepa-
rately was suggested to be dimeric [6], whereas we have
shown by various analyses, like size exclusion chromato-
graphy and analytical ultracentrifugation that the full
length PR-RT protein as well as the separate PR domain
of SFVmac are monomeric, and only transient PR
dimers are being formed [15] (Hartl MJ, Schweimer K,
Reger MH, Schwarzinger S, Bodem J, Rösch P, Wöhrl
BM: Formation of transient dimers by a retroviral pro-
tease, submitted).
Previous results obtained by sucrose density gradient
analyses with PR-RT purified from SFVmac particles
also indicated that the protein is monomeric [24]. To
clarify the monomer/dimer status of PFV PR-RT, we
performed size exclusion chromatography (Fig. 1B). Our
data revealed a single peak, which corresponded to a
m o l e c u l a rm a s so f8 5 . 4k D a .T h i si si ng o o da g r e e m e n t
with the theoretical molecular mass of the monomeric
PFV PR-RT of 86.5 kDa. Moreover, no dimer peak
Table 1 CD values
enzyme a-helix (%) b-sheet (%) b-turns (%) random coil (%) total (%)
PFV PR-RT 22 30 20 27 99
SFVmac PR-RT 22 29 20 28 99
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tions PFV PR-RT, like SFVmac PR-RT is monomeric to
a great extent (> 95%).
PR activity
Activity of retroviral PRs is only achieved when a sym-
metric homodimer is formed, since each subunit pro-
vides a conserved aspartate residue to form the active
center [23,25,26]. To detect residual PR activity we used
a substrate, denoted GB1-GFP, that consists of a fusion
protein between the immunoglobulin binding domain
B1 of the streptococcal protein G (GB1) and the green
fluorescent protein (GFP) enframing the natural
SFVmac Pol cleavage site YVVH↓CNTT. Although in
PFV Pol the His is exchanged by Asn, this substrate
could also be used for PFV PR-RT, because retroviral
PRs are able to recognize different cleavage sites.
A concentration of 3 M NaCl was used in the assay
since under these conditions SFVmac PR-RT revealed
the highest PR activity, and no activity was detected
when low salt concentrations (ca. 0.2 - 0.4 M NaCl)
were applied [15]. Fig. 2 illustrates that both proteins
were capable of almost completely cleaving the pro-
vided substrate even though the offered sequence is
d i f f e r e n tf r o mt h en a t u r a l l yoccurring cleavage site in
PFV Pol.
Size exclusion chromatography and PR activity assays
revealed a new feature special to spumaretrovirinae. FVs
appear to express a monomeric PR domain within the
Pol polyprotein which is catalytically inactive. In vitro
dimerization of the PR domain is inducible at high salt
concentrations. This effect might be caused by a hydro-
phobic dimerization interface, which under high ionic
strength disfavors the monomeric state.
Recently published results suggest that HIV-1 PR in the
Gag-Pol precursor is only present as a transient dimer
d u et oa ni n h i b i t o r ye f f e c to ft h et r a n s f r a m er e g i o n ,
which is located N-terminally of the PR domain [27].
Since there is no Gag-Pol fusion protein in FVs, an N-
terminal extension of the PR does not exist. Thus, the
regulation of the FV PR activity has to be different. We
have shown recently, that SFVmac PR forms transient
dimers at low salt concentrations. Obviously, in vivo PR
activation cannot be achieved by increasing the NaCl
concentration to 3 M, indicating that an additional cellu-
lar and/or viral factor must be involved in PR activation.
Characteristics of polymerization
A key step in the retroviral life cycle is the reverse tran-
scription of the genomic RNA into double stranded (ds)
DNA. For formation of dsDNA, the RT catalyzes RNA-
and DNA-dependent DNA polymerization to synthesize
the (-) and (+)-strand, respectively.
To further characterize the PR-RT enzymes, we per-
formed polymerization assays on the homopolymeric
poly(rA)/oligo(dT)15 substrate and on heteropolymeric
single-stranded M13 DNA. The incorporation of
3H-
TTP was used to determine Michaelis-Menten para-
meters. Comparison with values already published for
SFVmac PR-RT for homopolymeric substrates revealed
fairly similar KM-a n dk cat-values for the two enzymes.
Moreover, the KM-values for homo- and heteropoly-
meric substrates are comparable (Table 2) [14].
The KM values determined here for FV PR-RTs are ca.
5-30 fold higher than those published for HIV-1 RT
[28-30]. A recent publication compares the pre-steady-
state kinetics of PFV PR-RT with those of HIV-1 and
Figure 1 Biophysical properties of PFV and SFVmac PR-RT. (A)
Far UV circular dichroism (CD) spectra of wild-type SFVmac
(continuous line) and PFV PR-RT (dotted line) were acquired at 20°C
using a band width of 1 nm, a sensitivity of 100 mdeg and a data
density of 5 points/nm in a 0.1 cm cell with 0.5 μM of each enzyme
in 25 mM Na2HPO4/NaH2PO4 pH 7.4, and 5 mM NaCl. (B) Size
exclusion chromatography of PFV PR-RT using an S200 HR 10/30
column. The run was performed with 10 nmol PFV PR-RT in 50 mM
Na2HPO4/NaH2PO4 pH 7.4, 300 mM NaCl and 0.5 mM DTT. The inset
shows the fit to the data obtained for the molecular masses of the
standard proteins (open circles), which was used for the
determination of the molecular mass of PFV PR-RT (closed circle).
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kpol values of the three enzymes are similar, the disso-
ciation constants (KD) for dNTP binding are about 10 -
80 fold higher with PFV PR-RT as compared to HIV-1
RT, but are comparable to the affinities obtained for
MuLV RT [31]. These kinetic data together with our
results reveal different polymerization properties of
HIV-1 RT and FV PR-RTs. The data imply that DNA
polymerization of FV PR-RTs is poor at low dNTP con-
centrations. One reason for the differences observed
might be the fact that in contrast to FV, HIV-1 can
replicate in non-dividing cells, where dNTP concentra-
tions are low. In such an environment, polymerization
efficiency can be improved by RTs with high affinities
for dNTPs [31].
A qualitative analysis of DNA polymerization was per-
formed by using a heteropolymeric single stranded M13
DNA as a template together with a radioactively 5’ end
labeled primer and saturating dNTP concentrations of
150 μM. The polymerization products were compared
on a denaturing polyacrylamide/urea gel (Fig. 3). The
results confirmed the kinetic data foreshadowed in
Table 2, revealing a somewhat higher polymerization
efficiency of PFV-PR-RT.
Since polymerization activities are also dependent on
nucleic acid substrate affinities, we determined KD-
values of the two FV PR-RTs for DNA/RNA and
DNA/DNA by fluorescence anisotropy. In each of
these experiments a 24/40 mer primer/template (P/T)
substrate was used containing a fluorescent dye
Figure 2 PR activity assay. Reaction products were analyzed by 19% SDS-PAGE. 10 μM GB1-GFP substrate harboring a FV PR cleavage site
between GB1 and GFP was incubated with 10 μM SFVmac PR-RT or PFV PR-RT, respectively, at 37°C for 16 h in reaction buffer (50 mM
Na2HPO4/NaH2PO4 pH 7.4, 0.5 mM DTT, 3 M NaCl). C, control, substrate cleavage with TEV protease; (-), uncleaved substrate; M, molecular weight
standard. The sizes of the standard proteins are indicated on the left.

























PFV PR-RT 9.9 (± 1.6) 44.4 (± 3.0) 45 (± 12) 7.1 (± 0.9) 46 (± 9) 3 (± 0.3)
SFVmac PR-RT 32.4 (± 4.2)
3) 36.4 (± 2.4)
3) 40.1 (± 4.0)
3) 5.5 (± 0.3)
4) 45 (± 3) 4 (± 0.1)
1) KM and kcat-values, respectively, determined for TTP on the homopolymeric substrate poly(rA)/oligo(dT).
2) KM and kcat-values, respectively, determined for dNTPs on a heteropolymeric single stranded M13 substrate
3) Data adopted from [14]
4) vmax-value used for kcat calculation derived from [14].
Hartl et al. Retrovirology 2010, 7:5
http://www.retrovirology.com/content/7/1/5
Page 4 of 10(Dy-647) at the 5’ end of the template strand (Table 2,
Fig. 4). For both enzymes, the affinity for the DNA/
RNA P/T appeared to be higher than for DNA/DNA.
This effect was far more pronounced for PFV PR-RT
with a 4-fold lower KD-value for the DNA/RNA sub-
strate. Comparison with HIV-1 RT shows an unex-
pected difference, i.e. the affinities of HIV-1 RT for
nucleic acid substrates are much higher. For DNA/
DNA or DNA/RNA substrates KD-values of approxi-
mately 2 nM have been determined [32-34].
RNase H activity
The third enzymatic activity associated with PR-RT is its
RNase H activity, which is responsible for degradation of
the RNA strand of an RNA/DNA hybrid and is indis-
pensable in the reverse transcription process.
Polymerization-independent RNase H activity was
tested on two different substrates. First, Michaelis-Men-
ten-parameters were determined on a blunt-ended
RNA/DNA substrate containing a fluorescent dye on
the 3’ end of the RNA and a quencher on the 5’ end of
the DNA. Upon cleavage of the RNA the fluorescent
dye is released from the quencher resulting in an
increase in fluorescence intensity. By varying substrate
concentrations, KM-a n dk cat-values for RNase H activ-
ities were calculated (Table 3). SFVmac and PFV PR-RT
showed KM-values of 18.1 nM and 17.1 nM, respec-
tively. These are in the range of HIV-1 RT (25 nM) [35]
Figure 3 DNA-dependent DNA polymerase activity on a
heteropolymeric substrate. Reactions were carried out at 37°C for
the times indicated on top with 6 nM of the M13 P/T substrate, 85
nM of PFV or SFV PR-RT and 150 μM of each dNTP, analyzed by
denaturing gel electrophoresis on a 10% sequencing gel and
visualized by phosphoimaging. DNA size markers are marked on the
right. - RT, assay without enzyme;
Figure 4 Determination of KD-values by fluorescence
anisotropy measurements. 15 nM of a fluorescently labeled DNA/
DNA (black circle) or DNA/RNA (black square) P/T substrate was
titrated with PFV PR-RT at 25°C. The curves show the best fit to a
two component binding equation [14] describing the binding
equilibrium with KD-values shown in Table 2.
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substrate) [36]. Provided that indeed FV PR-RTs are less
abundant in the virus particle, it is remarkable that the
FV RNase H activities were not higher than those of
HIV-1 RT.
To determine the endonucleolytic RNase H cleavage
sites of the two PR-RTs qualitatively, a 40 mer RNA
hybridized to a 24 mer DNA was used (Fig. 5). A fluor-
escent dye at the 5’ end of the RNA allowed visualiza-
tion of the cleavage products after separation on 15%
sequencing gels. Our time course experiments indicated
that with both enzymes a primary endonucleolytic clea-
vage at position -19 was followed by a 3’ >5 ’ directed
processing reaction leading to shorter RNA products
(Fig. 5). Primary RNase H cleavage sites in the RNA at
positions 15 -20 nucleotides away from the primer ter-
minus of the hybrid were also detected for the RTs of
orthoretrovirinae like HIV-1 and RSV [37-42]. They are
directed by the 3’-end of the DNA-primer which binds
to the active site of the polymerase [43,44]. While RSV
RT appears to lack a 3’ >5 ’ directed processing activity
[37], SFVmac and PFV PR-RTs (Figure 5B) as well as
HIV-1 and MoMLV RTs degrade the RNA to 8 mers or
smaller products [41,45].
Conclusions
Our data reveal small differences of FV PR-RTs in their
catalytic activities and biophysical properties. The KM-
values determined for HIV-1 RT are 5-30 fold lower
than those for FV PR-RTs. These deviations in kinetic
behavior might be based on the fact that HIV-1 can
replicate in non-dividing cells. Remarkably, both FV PR-
RTs are monomeric in solution, implying that transient
dimers need to be formed in order to obtain PR activity.
Transient dimerization has been demonstrated recently
f o rS F V m a cP Ra n dw a ss u g g e s t e dt op l a yar o l ei nt h e
regulation of a timely activation of PR activity (Hartl
MJ, Schweimer K, Reger MH, Schwarzinger S, Bodem J,
Rösch P, Wöhrl BM: Formation of transient dimers by a
retroviral protease, submitted). Small structural and con-
sequently catalytic variations between the two FV PR-
RTs might account for the differences observed (e.g. in
the resistance to the nucleoside inhibitor AZT.) Further
structural and functional analyses will be necessary to
elucidate these findings.
Methods
Plasmid construction and protein purification
For SFVmac PR-RT, gene expression and protein purifi-
cation were performed as described previously [14]. The
plasmid pET101TOPO-PFV-PR-RT-6His was con-
structed using the Champion™ pET Directional TOPO®
Expression kit (Invitrogen, Darmstadt, Germany). The N-
terminus of the PFV PR-RT starts with the amino acids
MNPLQLLQPL corresponding to the N-terminus of the
PR gene. The C-terminus contains a 6 × His tag and
exhibits the following amino acid sequence: ATQG-
SYVVNA-6His. The plasmid was transformed into the
Escherichia coli (E. coli) strain BL21 (DE3) pREP4:
GroESL [46], expressing E. coli chaperone proteins to
facilitate folding of heterologous proteins. Cells were
grown at 37°C in LB medium supplemented with 100 μg/
ml ampicillin and 34 μg/ml kanamycin to an optical den-
sity of 600 nm (OD600) of ca. 0.8. The temperature was
reduced to 16°C until an OD600of ca. 1.0 was reached.
Expression of the recombinant PFV PR-RT-6His gene
was then induced by the addition of 0.2 mM isopropyl-
thiogalactoside (IPTG) at 16°C over night. Cells were har-
vested by centrifugation at 5000 g for 20 min at 4°C.
Purification of SFVmac and PFV PR-RT
SFVmac PR-RT was purified as described previously
[14]. PFV PR-RT was purified as follows by a combina-
tion of Ni-affinity and hydrophobic interaction
chromatography:
Ni-NTA affinity chromatography
Cells were resuspended in 50 mM Na-phosphate pH 7.4,
300 mM NaCl, 10 mM imidazole, 0.5 mM dithiothreitol
(DTT). After addition of lysozyme, DNase I and one
protease inhibitor cocktail tablet (Complete, EDTA-free,
Roche Diagnostics GmbH, Mannheim) the suspension
was stirred on ice for 30 min. After cell lysis using a
microfluidizer (Microfluidics, Newton, MA, USA) the
suspension was centrifuged at 19100 g for 30 min at 4°
C. Purification of the protein was performed by a step
gradient applying increasing concentrations of up to 500
mM imidazole on a HisTrap column (HisTrap, GE
Healthcare, München, Germany).
Hydrophobic interaction chromatography
Fractions containing PFV PR-RT were pooled and dia-
lyzed (Spectra/Por, MWCO 50 000 Da) twice for at
least 2 h against 50 mM Na-phosphate pH 7.4, 300 mM
NaCl, 1 M (NH4)2SO4 and 0.5 mM DTT and then
loaded onto a 5 ml butyl column (ButylFF, GE Health-
care, München, Germany). The protein was eluted by
applying a step gradient from 1 M (NH4)2SO4 and 300
mM NaCl to 0 M (NH4)2SO4 and 0 M NaCl. After elec-
trophoresis of the fractions on 10% SDS-polyacrylamide
gels the relevant fractions were concentrated with
Table 3 Kinetic parameters of the RNase H activities of





PFV PR-RT 17.1 (± 1.2) 0.017 (± 0.0003)
SFVmac PR-RT 18.1 (± 0.6) 0.020 (± 0.0003)
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volume of 200 μl and dialyzed against 50 mM Na-phos-
phate pH 7.4, 100 mM NaCl 0.5 mM DTT.
Analyses using circular dichroism (CD) spectra and
size exclusion chromatography were performed with
freshly purified SFVmac and PFV PR-RT. For PR, poly-
merization and RNase H measurements the PFV PR-RT
was dialyzed (Spectra/Por, MWCO 50 000 Da) against
50 mM Na-phosphate pH 7.4, 100 mM NaCl, 0.5 mM
DTT and 15% glycerol over night, the glycerol concen-
tration was then increased to 50% and the protein
stored at -20°C.
Peptide mass fingerprint (PMF) analysis
Protein bands of ca. 1 mm × 3 mm were excised from
10% SDS-polyacrylamide gels and the integrity and iden-
tity of PFV PR-RT was confirmed by peptide mass finger-
printing (ZMMK Köln, Zentrale Bioanalytik, Germany).
Circular dichroism
Far UV circular dichroism (CD) spectra of wild-type
SFVmac and PFV PR-RT were acquired at 20°C using a
Jasco J-810 spectropolarimeter (Japan Spectroscopic,
Gross-Umstadt, Germany) at a band width of 1 nm, a
sensitivity of 100 mdeg and a data density of 5 points/
Figure 5 Qualitative RNase H assay. The DNA/RNA P/T substrate is shown on top. The cleavage sites determined for SFV and PFV PR-RT are
indicated by arrows. 320 nM of DY-647 labeled P/T substrate was incubated with 50 nM of SFVmac or PFV PR-RT in 50 mM Tris/HCl, pH8.0, 80 mM
KCl, 6 mM MgCl2 for the times indicated on top of the gel. Reaction products were analyzed on a 15% polyacrylamide sequencing gel and
visualized by detection of the fluorescence emission of the RNA template strand at 670 nm upon excitation at 633 nm. The cleavage sites are
indicated on the left. The first nucleotide of the RNA hybridized to the 3’-OH nucleotide of the DNA primer is denoted -1. The partially hydrolyzed
RNA on the right was used for the determination of the cleavage sites. Numbers on the right indicate the length of the RNA in nucleotides.
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sured in 25 mM Na-phosphate pH 7.4 and 5 mM NaCl.
At least 12 scans in the range between 260 and 190 nm
were averaged for each measurement, and the resulting
spectrum was smoothed and normalized to a mean resi-
dual weight ellipticity [ΘMRW] (deg·cm
2·dmol
-1)u s i n g
Jasco Spectra Manager Software. For secondary struc-
ture predictions based on the CD data the program
CDSSTR (Dichroweb) [14,27] was used.
Size exclusion chromatography
For analytical gel filtration of PFV PR-RT a Superdex
200 HR 10/30 column (GE Healthcare, Munich,
Germany) calibrated with catalase (232 kDa), aldolase
(158 kDa), ovalbumine (43 kDa) and chymotrypsinogen
(25 kDa) (GE Healthcare, Munich, Germany) was used
at a flow rate of 0.5 ml/min. The column was loaded
with 10 nmol PFV PR-RT in 50 mM Na2HPO4/
NaH2PO4 pH 7.4, 300 mM NaCl and 0.5 mM DTT.
PR activity assay
PR activity was measured as described before using a
substrate which contained the SFVmac Pol cleavage
site ATQGSYVVH↓CNTTP that can also be used by
PFV PR-RT. Control digests with TEV protease were
performed with the same substrate since it harbors a
TEV cleavage site adjacent to the FV PR cleavage site
[15].
Polymerization assays
RNA-dependent DNA polymerase activity was quantitated
on a poly(rA)/oligo(dT)15 substrate (0.2 U/ml) (Roche
Diagnostics GmbH, Mannheim, Germany) in a standard
assay (30 μl reaction volume) as described previously [14].
For the determination of KM,v max and kcat values, reac-
tions were performed with increasing concentrations of
TTP of 25, 50, 75,125 or 250 μM. For the determination
of kinetic parameters on a heteropolymeric substrate 100
nM of single stranded M13mp18 DNA and 15 nM of PR-
RT was used. dNTP concentrations of 25, 50, 75, 125 and
250 μM were added, using [3H]-TTP (3000 Ci/mmol,
Hartmann Analytic GmbH, Braunschweig, Germany) as a
tracer. KM-values were calculated by linear regression
using Eadie-Hofstee plots. kcat is defined as vmax/enzyme
concentration. Qualitative DNA polymerization assays on
denaturing polyacrylamide/urea gels using single stranded
M13mp18 DNA as a substrate were performed as
described previously [14].
Fluorescence anisotropy measurements
Fluorescence equilibrium titrations were performed to
determine the dissociation constants (KD)f o rn u c l e i c
acid binding with a 24/40 mer DNA/DNA or DNA/
RNA primer/template (P/T). Experiments and data
fitting were carried out as described [14] with15 nM
fluorescently labeled P/T at 25°C.
RNase H activity assays
Substrate preparation
The RNA-strand 5’-CCG AUG GCU CUC CUG GUG
AUC CUU UCC-6-FAM (6-carboxy-fluorescein) and the
DNA-strand 5’-Dabcyl-GGA AAG GAT CAC CAG
GAG AG were synthesized by biomers.net (Ulm, Ger-
many). The hybrid was formed by mixing the two oligo-
nucleotides at a ratio of 1:1.2 respectively in 20 mM
Tris/HCl pH 8.0 and 20 mM NaCl, followed by heating
at 95°C for 2 min and cooling down to room tempera-
t u r eo v e rat i m ep e r i o do f2h .T h er e s u l t i n gs u b s t r a t e
was stored in aliquots at -20°C.
RNase H enzyme kinetics
Steady-state fluorescence measurements were performed
at 25°C on a Fluorolog-Tau-3 spetrofluorometer (HOR-
I B AJ o b i nY v o nG m b H ,U n t e r h a c h i n g ,G e r m a n y ) .T h e
assay was carried out in a total volume of 1.2 ml con-
taining 50 mM Tris/HCl pH 8.0, 80 mM KCl, 6 mM
MgCl2 and a final concentration of 1 nM PR-RT. To
determine the Michaelis-Menten kinetic parameters the
DNA-dabcyl/RNA-6-FAM P/T concentration was varied
from 10 to 200 nM. Cleavage of the RNA in the hybrid
leads to dissociation of a fluorescein labeled RNA frag-
ment from the dabcyl quencher and thus to a fluores-
cence increase. Upon excitation of the substrate at 495
nm an increase in fluorescence emission can be detected
at 520 nm. The maximum change in fluorescence inten-
sity and thus complete substrate cleavage was deter-
mined by incubating the hybrid with a large excess of
PR-RT (250 nM). Initial rates were calculated using the
linear slope of the reaction progress curve where less
than 5% of substrate was cleaved. Values for kinetic
parameters (KM and vmax)w e r eo b t a i n e db yl i n e a r
Eadie-Hofstee regression of the Michaelis-Menten equa-
tion V0 =V max·[S0]/(Km+[ S 0]). kcat is defined as vmax/
enzyme concentration.
Qualitative RNase H assay
The gelelectrophoretic assay used a 5’ fluorescently labeled
RNA-oligonucleotide (5’- [DY-647]-CUA AUU CCG CUU
UCC CCU CUC CUG GUG AUC CUU UCC AUC C;
biomers.net, Ulm, Germany), which was purified on a 20%
denaturing polyacrylamide gel and then annealed to the
unlabeled DNA-oligonucleotide 5’-GGA AAG GAT CAC
CAG GAG AGG GGA (biomers.net, Ulm, Germany). The
hybrid was formed by mixing 2 μM Dye647-RNA with 2.4
μM DNA primer in 20 mM Tris/HCl pH 8.0 and 20 mM
NaCl, followed by heating at 95°C for 2 min and cooling at
room temperature over a time period of 2 h. The RNase H
reaction was performed at 37°C in a total volume of 30 μl
in 50 mM Tris/HCl pH 8.0, 80 mM KCl and 6 mM MgCl2
with 320 nM P/T substrate. The reaction was initiated by
Hartl et al. Retrovirology 2010, 7:5
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Page 8 of 10the addition of 50 nM PR-RT. Aliquots were removed at
different time points and analyzed by electrophoresis on a
15% polyacrylamide sequencing gel. Products were visua-
lized by fluorescence emission at 670 nm upon excitation
at 633 nm using a fluorescence laser scanner (FLA 3000,
raytest, Straubenhardt, Germany).
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